title: Review: Antiplatelet drugs: what comes next?
abstract: Antiplatelet drugs are important components in the management of atherothrombotic vascular disease. However, several limitations restrict the safety and efficacy of current antiplatelet therapy in clinical practice. Interpatient variability and resistance to aspirin and/or clopidogrel has spurred efforts for the development of novel agents. Indeed, several antiplatelet drugs are at various stages of evaluation; those at advanced stage of development are the focus of this review.
authors.affiliation: Department of Internal Medicine, University of Ioannina Medical School, Ioannina, Greece.
authors.forename: Anastazia A
authors.initials: AA
authors.lastname: Kei
authors.forename: Matilda
authors.initials: M
authors.lastname: Florentin
authors.forename: Dimitri P
authors.initials: DP
authors.lastname: Mikhailidis
authors.forename: Moses S
authors.initials: MS
authors.lastname: Elisaf
authors.forename: Evangelos N
authors.initials: EN
authors.lastname: Liberopoulos
mesh_terms: D000818:Animals; D004342:Drug Hypersensitivity / Q000209:etiology; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects* / Q000145:classification* / Q000627:therapeutic use*; D013927:Thrombosis / Q000188:drug therapy / Q000401:mortality
chemical_list: D010975:Platelet Aggregation Inhibitors